XELIRINOX Regimen a Triple Combination of XELoda, IRINotecan and OXaliplatin in First-line Treatment of Metastatic Pancreatic Adenocarcinoma | Zendy

AI Assistant Blog Pricing

Open Access

XELIRINOX Regimen a Triple Combination of XELoda, IRINotecan and OXaliplatin in First-line Treatment of Metastatic Pancreatic Adenocarcinoma

Author(s) -

Haider Y. Shukur

Publication year - 2020

Publication title -

cancer and oncology research

Language(s) - English

Resource type - Journals

eISSN - 2331-6128

pISSN - 2331-6136

DOI - 10.13189/cor.2020.060101

Subject(s) - oxaliplatin , irinotecan , medicine , oncology , regimen , colorectal cancer , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.